CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 96 enrolled
Drug / intervention
Cetuximab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02101034
NCT02101034Phase 2Completed
CompareCT.gov

Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN

Washington University School of Medicine·interventional·Posted Apr 1, 2014·Updated Dec 21, 2023

In Brief

A Phase 2 clinical trial evaluating Cetuximab and PD 0332991 for Carcinoma, Squamous Cell of Head and Neck. Completed, enrolled 96 participants across 5 sites.

Detailed Summary

The purpose of this Phase I/II study is to define the maximum tolerated dose of PD 0332991 given with cetuximab and evaluated the side effects of the combination.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Squamous Cell of Head and Neck
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 1, 2014
Enrollment StartJun 17, 2014
Primary CompletionJun 8, 2020
Study CompletionNov 10, 2023
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 12.3 years ago

Interventions

Cetuximabbiological

PD 0332991drug